Sino Biopharmaceutical (HK:1177) has released an update.
Sino Biopharmaceutical has announced the successful completion of a pivotal clinical trial for its innovative drug Rovadicitinib Tablet, aimed at treating moderate to high-risk myelofibrosis, and the subsequent acceptance of its new drug application by China’s drug regulatory authority. The Rovadicitinib Tablet, a self-developed JAK/ROCK inhibitor, shows promise in inhibiting tumor activity and has also demonstrated efficacy in treating chronic graft-versus-host disease. The company is expanding clinical research to further establish the drug’s therapeutic potential.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
